Abstract IA012: Modeling prostate cancer metastasis in genetically engineered mouse models

Abstract My laboratory has a longstanding interest in developing mouse models of prostate cancer that recapitulate the broad spectrum of prostate cancer phenotypes. We have been employing state-of-the-art systems biology approaches to integrate molecular data from our mouse models with comparable data from human prostate cancer, with the ultimate goal of informing patient care. This is exemplified by our recent description of OncoLoop, a transcriptomic framework that can support rapid-turnaround co-clinical studies to identify and validate drugs for individual patients. Our current studies have largely focused on modeling metastatic prostate cancer, particularly metastasis to bone. We have generated genetically engineered mouse models, as well as syngeneic allograft models, that model bone metastasis with high penetrance. In addition, we are employing an “organ-on-a-chip” platform that simulates bone tropism. We are using these models to decipher the molecular mechanisms that drive metastatic dissemination and bone metastasis. My presentation at this AACR conference will focus on how we have been using these various models to study circulating tumor cells (CTCs). In particular, I will describe our recent studies in which we have been using single-cell sequencing of CTCs and have generated CTC-derived organoids to interrogate mechanisms that drive dissemination and metastasis. Citation Format: Cory Abate-Shen, Arianna Giacobbe, Aleksandar Obradovic, Alessandro Vasciaveo, Florencia Picech, Kacey Ronaldson-Bouchard, Gordana Vunjak-Novakovic, Michael M. Shen, Andrea Califano, Peter Sims. Modeling prostate cancer metastasis in genetically engineered mouse models [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr IA012.